Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIG1 hypoxia inducible domain family member 1A pseudogene 2 (HIGD1AP2) is classified as a pseudogene, not as a protein-coding gene or functional molecular target[4][6]. Pseudogenes are non-functional segments of DNA that resemble functional genes but do not encode active proteins. The canonical gene in this family, HIGD1A, is a mitochondrial inner membrane protein involved in mitochondrial homeostasis, cell survival under stress, and hypoxia-inducible responses[2]. In contrast, HIGD1AP2 lacks evidence of protein product or direct disease association, drug interaction, or biological function and is not considered a therapeutic target[4][6]. There appear to be no recognized aliases beyond its official abbreviation, and no structured evidence links it to pharmacological or biomarker utility. Note: The entry is considered "incorrect" in the sense that pseudogenes like HIGD1AP2 do not encode functional targets relevant for drug development or therapeutic intervention. The functional information about the HIGD1A protein does not apply to HIGD1AP2[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIG1 hypoxia inducible domain family member 1A pseudogene 2 (HIGD1AP2).